Anthera Pharmaceuticals, Inc.
ANTH
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.62K
Close$
Share Statistics
| Market cap | $2,618.00 |
|---|---|
| Enterprise Value | $-8,083,382.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.65 |
| Beta | -123.12 |
| Outstanding Shares | 22,166,869 |
Return
| Return on Equity | -180.63% |
|---|---|
| Return on Assets | -111.95% |
| Return on Invested Capital | -377.49% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.35 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Anthera Pharmaceuticals, Inc.
21 employees
CEO: Mr. Paul F. Truex M.B.A. Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replac...